ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0357

Evaluating Meaningful Within-Person Change Thresholds in PROMIS-Fatigue Scores from Three Phase 3 Clinical Trials of Sarilumab for Rheumatoid Arthritis Using Empirical Cumulative Distribution Function (eCDF) Curves

Clifton Bingham1, Emily Molina2, Amy Praestgaard3, Stefano Fiore3 and David Cella4, 1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins, Baltimore, MD, 3Sanofi, Bridgewater, NJ, 4Northwestern University, Chicago, IL

Meeting: ACR Convergence 2024

Keywords: clinical trial, Fatigue, Outcome measures, Patient reported outcomes, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Patient Outcomes, Preferences, & Attitudes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: To evaluate changes over time in fatigue measured by Patient Reported Outcome Measures Information System (PROMIS)-Fatigue scores in rheumatoid arthritis (RA) patients treated with sarilumab, and to assess the proportion of patients achieving different meaningful within-person change thresholds.  

Methods: Data from the three Phase 3 randomized controlled trials of sarilumab in RA were evaluated. The 10 RA-relevant items from the 13-item Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) were scored on the PROMIS T-score metric using a pattern-scoring method. Mean changes in PROMIS-Fatigue-10a were compared, proportions of patients achieving meaningful within-person change thresholds were assessed, and results were visualized using empirical cumulative distribution function (eCDF) curves.

Results: RA patients reported high baseline fatigue. Using PROMIS-Fatigue-10a, at week 24, patients receiving sarilumab 150 or 200 mg every other week had rapidly improved mean levels of fatigue compared with placebo. When compared with adalimumab, patients receiving sarilumab had more improvement. eCDF curves showed separation between active treatment vs placebo with both sarilumab doses and across the score range for improvement (Figure 1). Higher proportions of patients achieved 3-, 5-, and 7-point improvements in PROMIS-fatigue in active treatment groups.

Conclusion: Substantial proportions of RA patients treated with sarilumab achieved meaningful change in fatigue measured by PROMIS-Fatigue-10a over time. This study demonstrates the convertibility of FACIT-Fatigue into the PROMIS T-score metric, the rapid reduction in fatigue with biological therapies , and the use of novel eCDF curves to show individual patient level change.

Supporting image 1

Figure 1, a-c. Empirical cumulative distribution function (eCDF) curves for change from baseline to 24-weeks in PROMIS-Fatigue 10a scores in (a) MOBILITY, (b) TARGET and (c) MONARCH trials.


Disclosures: C. Bingham: AbbVie/Abbott, 2, Bristol-Myers Squibb(BMS), 5, Eli Lilly, 2, sanofi, 2; E. Molina: None; A. Praestgaard: Sanofi, 3, 11; S. Fiore: sanofi, 3, 11; D. Cella: None.

To cite this abstract in AMA style:

Bingham C, Molina E, Praestgaard A, Fiore S, Cella D. Evaluating Meaningful Within-Person Change Thresholds in PROMIS-Fatigue Scores from Three Phase 3 Clinical Trials of Sarilumab for Rheumatoid Arthritis Using Empirical Cumulative Distribution Function (eCDF) Curves [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/evaluating-meaningful-within-person-change-thresholds-in-promis-fatigue-scores-from-three-phase-3-clinical-trials-of-sarilumab-for-rheumatoid-arthritis-using-empirical-cumulative-distribution-function/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluating-meaningful-within-person-change-thresholds-in-promis-fatigue-scores-from-three-phase-3-clinical-trials-of-sarilumab-for-rheumatoid-arthritis-using-empirical-cumulative-distribution-function/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology